“Sure. So as you just said, just to level set, you see high single-digit growth here in China, both for Q3 and we anticipate a similar level in Q4.”

In context

“e for that application. So, we are confident that the strength of this market and its fundamentals, remain very, very strong. Biologics, in all the modalities that we've talked about are very underpenetrated in the market, and it is a matter of getting the penetration up launching the new products in the pipeline that we'll continue to drive the growth of this market despite the reset that we see going on in the supply chain. Operator: We'll take our next question from Dan Leonard with Credit Suisse. Dan Leonard: So my first question, Rainer, I was hoping you could elaborate on trends in China across your different OpCos? I think you said growth was high single digits in total, but flagged some weakness in diagnostic. So just wondering, if you could offer more color by OpCo? Rainer Blair: Sure. So as you just said, just to level set, you see high single-digit growth here in China, both for Q3 and we anticipate a similar level in Q4. And that's really a broad-based strength there. Let me start with Diagnostics where we did see patient volumes impacted by these rolling shutdowns. So this zero COVID policy shutdown that you're likely reading about in China. So that affected patient volumes and think of those as being 90% to 95% of what they were in 2021. And we're working through those and continue to see China as really a very, very strong market. Now lastly, the rest of our business continues to be very, very strong. As you think about life science instruments, as you think about EAS, as you think about the diagnostics, the other diagnostics companies, we continue to see robust demand there. And as patient volumes normalize, which we expect to happen sometime in the next year, we're confident that China continues to b”